Interestingly, JQ1, an pharmacological inhibitor of BRD4, is able to delay disease progression in AML-bearing mice at doses that showed only minimal effects on normal hematopoiesis [23]. This evidence concerns the gene BRD4 and acute myeloid leukemia.